vs
Side-by-side financial comparison of CONSTELLIUM SE (CSTM) and BeOne Medicines Ltd. (ONC). Click either name above to swap in a different company.
CONSTELLIUM SE is the larger business by last-quarter revenue ($2.2B vs $1.5B, roughly 1.5× BeOne Medicines Ltd.). CONSTELLIUM SE runs the higher net margin — 5.1% vs 4.4%, a 0.6% gap on every dollar of revenue. BeOne Medicines Ltd. produced more free cash flow last quarter ($379.8M vs $109.0M).
Constellium SE is an American-Swiss, French-based global manufacturer of aluminium rolled products, extruded products, and structural parts based on a large variety of advanced alloys. Constellium's C-TEC research center has been credited for advancing technology in the field of advanced aluminium alloy. Constellium primarily serves the aerospace, automotive, and packaging sectors. Large clients include Mercedes-Benz, Audi, BMW, Fiat Chrysler Automotive, Ford, Airbus, Boeing, and Bombardier.
BeOne Medicines Ltd.ONCEarnings & Financial Report
BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment.
CSTM vs ONC — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $2.2B | $1.5B |
| Net Profit | $112.0M | $66.5M |
| Gross Margin | — | 90.5% |
| Operating Margin | 7.5% | 12.4% |
| Net Margin | 5.1% | 4.4% |
| Revenue YoY | — | 32.8% |
| Net Profit YoY | — | 143.8% |
| EPS (diluted) | $0.79 | $0.05 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $2.2B | $1.5B | ||
| Q3 25 | $2.2B | $1.4B | ||
| Q2 25 | $2.1B | $1.3B | ||
| Q1 25 | $2.0B | $1.1B | ||
| Q4 24 | — | $1.1B | ||
| Q3 24 | — | $1.0B | ||
| Q2 24 | $1.9B | $929.2M | ||
| Q1 24 | — | $751.7M |
| Q4 25 | $112.0M | $66.5M | ||
| Q3 25 | $88.0M | $124.8M | ||
| Q2 25 | $36.0M | $94.3M | ||
| Q1 25 | $37.0M | $1.3M | ||
| Q4 24 | — | $-151.9M | ||
| Q3 24 | — | $-121.3M | ||
| Q2 24 | $76.0M | $-120.4M | ||
| Q1 24 | — | $-251.2M |
| Q4 25 | — | 90.5% | ||
| Q3 25 | — | 86.1% | ||
| Q2 25 | — | 87.5% | ||
| Q1 25 | — | 85.2% | ||
| Q4 24 | — | 85.8% | ||
| Q3 24 | — | 83.0% | ||
| Q2 24 | — | 85.1% | ||
| Q1 24 | — | 83.4% |
| Q4 25 | 7.5% | 12.4% | ||
| Q3 25 | 5.8% | 11.5% | ||
| Q2 25 | 2.7% | 6.7% | ||
| Q1 25 | 3.1% | 1.0% | ||
| Q4 24 | — | -7.0% | ||
| Q3 24 | — | -12.0% | ||
| Q2 24 | 5.4% | -11.5% | ||
| Q1 24 | — | -34.8% |
| Q4 25 | 5.1% | 4.4% | ||
| Q3 25 | 4.1% | 8.8% | ||
| Q2 25 | 1.7% | 7.2% | ||
| Q1 25 | 1.9% | 0.1% | ||
| Q4 24 | — | -13.5% | ||
| Q3 24 | — | -12.1% | ||
| Q2 24 | 3.9% | -13.0% | ||
| Q1 24 | — | -33.4% |
| Q4 25 | $0.79 | $0.05 | ||
| Q3 25 | $0.62 | $0.08 | ||
| Q2 25 | $0.25 | $0.06 | ||
| Q1 25 | $0.26 | $0.00 | ||
| Q4 24 | — | $-0.10 | ||
| Q3 24 | — | $-0.09 | ||
| Q2 24 | $0.51 | $-0.09 | ||
| Q1 24 | — | $-0.19 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $120.0M | $4.5B |
| Total DebtLower is stronger | $1.9B | $836.4M |
| Stockholders' EquityBook value | $952.0M | $4.4B |
| Total Assets | $5.4B | $8.2B |
| Debt / EquityLower = less leverage | 2.00× | 0.19× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $120.0M | $4.5B | ||
| Q3 25 | $122.0M | $4.0B | ||
| Q2 25 | $133.0M | $2.8B | ||
| Q1 25 | $118.0M | $2.5B | ||
| Q4 24 | — | $2.6B | ||
| Q3 24 | — | $2.7B | ||
| Q2 24 | — | $2.6B | ||
| Q1 24 | — | $2.8B |
| Q4 25 | $1.9B | $836.4M | ||
| Q3 25 | $2.0B | — | ||
| Q2 25 | $2.0B | — | ||
| Q1 25 | $1.9B | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $952.0M | $4.4B | ||
| Q3 25 | $845.0M | $4.1B | ||
| Q2 25 | $780.0M | $3.8B | ||
| Q1 25 | $745.0M | $3.5B | ||
| Q4 24 | — | $3.3B | ||
| Q3 24 | — | $3.4B | ||
| Q2 24 | $796.0M | $3.4B | ||
| Q1 24 | — | $3.4B |
| Q4 25 | $5.4B | $8.2B | ||
| Q3 25 | $5.4B | $7.6B | ||
| Q2 25 | $5.4B | $6.3B | ||
| Q1 25 | $5.2B | $5.8B | ||
| Q4 24 | — | $5.9B | ||
| Q3 24 | — | $5.8B | ||
| Q2 24 | — | $5.7B | ||
| Q1 24 | — | $5.7B |
| Q4 25 | 2.00× | 0.19× | ||
| Q3 25 | 2.34× | — | ||
| Q2 25 | 2.53× | — | ||
| Q1 25 | 2.56× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $218.0M | $417.3M |
| Free Cash FlowOCF − Capex | $109.0M | $379.8M |
| FCF MarginFCF / Revenue | 5.0% | 25.4% |
| Capex IntensityCapex / Revenue | 5.0% | 2.5% |
| Cash ConversionOCF / Net Profit | 1.95× | 6.28× |
| TTM Free Cash FlowTrailing 4 quarters | $159.0M | $941.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $218.0M | $417.3M | ||
| Q3 25 | $99.0M | $402.6M | ||
| Q2 25 | $114.0M | $263.6M | ||
| Q1 25 | $58.0M | $44.1M | ||
| Q4 24 | — | $75.2M | ||
| Q3 24 | — | $188.4M | ||
| Q2 24 | $138.0M | $-95.6M | ||
| Q1 24 | — | $-308.6M |
| Q4 25 | $109.0M | $379.8M | ||
| Q3 25 | $24.0M | $354.5M | ||
| Q2 25 | $37.0M | $219.8M | ||
| Q1 25 | $-11.0M | $-12.3M | ||
| Q4 24 | — | $-17.3M | ||
| Q3 24 | — | $54.7M | ||
| Q2 24 | $54.0M | $-205.5M | ||
| Q1 24 | — | $-465.1M |
| Q4 25 | 5.0% | 25.4% | ||
| Q3 25 | 1.1% | 25.1% | ||
| Q2 25 | 1.8% | 16.7% | ||
| Q1 25 | -0.6% | -1.1% | ||
| Q4 24 | — | -1.5% | ||
| Q3 24 | — | 5.5% | ||
| Q2 24 | 2.8% | -22.1% | ||
| Q1 24 | — | -61.9% |
| Q4 25 | 5.0% | 2.5% | ||
| Q3 25 | 3.5% | 3.4% | ||
| Q2 25 | 3.7% | 3.3% | ||
| Q1 25 | 3.5% | 5.0% | ||
| Q4 24 | — | 8.2% | ||
| Q3 24 | — | 13.3% | ||
| Q2 24 | 4.3% | 11.8% | ||
| Q1 24 | — | 20.8% |
| Q4 25 | 1.95× | 6.28× | ||
| Q3 25 | 1.13× | 3.22× | ||
| Q2 25 | 3.17× | 2.79× | ||
| Q1 25 | 1.57× | 34.71× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 1.82× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CSTM
| Packaging Rolled Products | $1.0B | 46% |
| Automotive Rolled Products | $318.0M | 14% |
| Aerospace Rolled Products | $270.0M | 12% |
| Transportation Industry Defense And Other Rolled Products | $232.0M | 11% |
| Automotive Extruded Products | $220.0M | 10% |
| Other Extruded Products | $132.0M | 6% |
| Specialty And Other Thin Rolled Products | $22.0M | 1% |
ONC
Segment breakdown not available.
